Delivery Order SPE2DB22D3011-SPE2DB25FQ2PX
- Not listed
- The Defense Logistics Agency awarded a $1,542.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for 500mL units of 70% dextrose-water intravenous solution. This delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, is a non-set-aside award issued under competitive procedures. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,047.24 to AmerisourceBergen Drug Corp for Dextrose 5%-Water IV Solution 50mL on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,947.02 to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Dextrose 50%-Water Syringe 50ML, with completion expected by November 14, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed out of AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,600.80 to AmerisourceBergen Drug Corp for the supply of Dextrose 50%-Water Syringe 50mL on November 20, 2025, with an ultimate completion date of November 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the agency's procurement processes. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dextrose 5%-LR IV Solution in 1000ml containers, with a contract ceiling value of $2,184.84. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,117 to Amerisourcebergen Drug Corporation for Dextrose 5%-Water intravenous solution in 50ml bottles. The contract has a period of performance from September 20th through September 21st, 2023. Amerisourcebergen will fulfill the order from its facility located in Conshohocken, Pennsylvania. No additional details were provided regarding major subcontractors or whether the award has any set aside...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dextrose 50%-Water Syringe 50ML, with a ceiling value of $1,339.90. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 29, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a major pharmaceutical distributor and healthcare...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $2,009.85 by the Defense Logistics Agency's Medical Supply Chain for Dextrose 50%-Water Syringe 50ML. The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency Troop Support Medical awarded a $124,350 delivery order to Amerisourcebergen Drug Corporation for 500ml bags of 5% dextrose in water intravenous solution. The contract has a firm fixed price and calls for delivery to Amerisourcebergen's facility in Conshohocken, Pennsylvania between August 25-28, 2023. The Defense Logistics Agency manages the Department of Defense's global supply chain and supports procurement for medical supplies. This delivery order was issued...
- The Defense Logistics Agency awarded a $155,540 delivery order to Amerisourcebergen Drug Corporation for Dextrose 50% in Water syringes. The firm fixed price order is for procurement of 50 milliliter syringes of the intravenous solution. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a period from July 24, 2023 through July 25, 2023. As a major provider of medical supplies to the Department of Defense, this order for intravenous fluids supports the...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2PXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,247.46 to AmerisourceBergen Drug Corp for Dextrose 5%-Water intravenous solution in 50ml units. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 8, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999 prime vendor agreement extending through December 2026 that supports global pharmaceutical supply for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive portfolio of medications, vaccines, and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The dextrose solution represents a standard medical commodity within the company's extensive therapeutic product offerings.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/5/25 |